Einzeltreffer — DigiBib

The Burkitt's lymphoma line Daudi carries a nontransforming Epstein-Barr virus (EBV) strain that has a deletion in the BamHI WYH region of the genome coding for the EBV nuclear antigen 2 (EBNA-2). Daudi cells fail to express the EBV-encoded latent membrane protein (LMP) (D. Ghosh and E. Kieff, J. Virol. 64:1855-1858, 1990). We show that LMP expression can be up regulated by exposure to n-butyrate and by superinfection with the B95-8 (B virus)- and P3HR1 (P virus)-derived EBV strains. Two LMP polypeptides of 60 and 48 kilodaltons (kDa) were detected in immunoblots of Daudi cells that had been exposed to 3 mM n-butyrate for 24 h. The intensity of the 48-kDa LMP increased during 72 h, in parallel with the appearance of early antigen-positive cells. The 60-kDa LMP was expressed at a low level and remained constant. Superinfection of Daudi cells with B and P virus induced the 60-kDa LMP within 3 h. In addition, P virus induced the 48-kDa LMP at a low level. The B virus-encoded EBNA-2 and EBNA-5 were detected 12 h after superinfection. The B virus-encoded 63-kDa LMP was coexpressed with the endogenous LMP after 48 h. Inactivation of the virus by UV illumination abolished the expression of the B virus-encoded antigens but did not affect the induction of the endogenous LMP. The B-cell activation marker CD23 was up regulated by B virus superinfection but not by n-butyrate exposure. CD23 was also expressed at a higher level in a stable B virus-converted subline, E95A-Daudi, that was EBNA-2 positive and coexpressed the Daudi virus- and B virus-encoded LMP. The results suggest that LMP expression is regulated by the interaction of cellular and viral factors. Binding of the virus to its membrane receptor might be involved in the triggering of cellular control mechanisms. Viral gene products are not directly involved in this function but may contribute to create a permissive cellular environment for LMP expression.

Titel:	Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection.
Autor/in / Beteiligte Person:	Contreras-Salazar, B ; Ehlin-Henriksson, B ; Klein, G ; Masucci, MG
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of virology, Jg. 64 (1990-11-01), Heft 11, S. 5441-7
Veröffentlichung:	Washington Dc : American Society For Microbiology ; <i>Original Publication</i>: Baltimore, American Society for Microbiology., 1990
Medientyp:	academicJournal
ISSN:	0022-538X (print)
DOI:	10.1128/JVI.64.11.5441-5447.1990
Schlagwort:	Antigens, CD analysis Antigens, Differentiation, B-Lymphocyte analysis Antigens, Viral analysis B-Lymphocytes physiology Burkitt Lymphoma Epstein-Barr Virus Nuclear Antigens Humans Lymphocyte Activation Membrane Proteins genetics Receptors, Fc analysis Receptors, IgE Tumor Cells, Cultured Up-Regulation Antigens, Viral genetics Butyrates pharmacology Gene Expression Regulation, Viral drug effects Herpesviridae Infections physiopathology Herpesvirus 4, Human genetics Viral Matrix Proteins
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Language: English [J Virol] 1990 Nov; Vol. 64 (11), pp. 5441-7. MeSH Terms: Viral Matrix Proteins* ; Antigens, Viral / genetics ; Butyrates / pharmacology ; Gene Expression Regulation, Viral / drug effects ; Herpesviridae Infections / physiopathology ; Herpesvirus 4, Human / *genetics ; Antigens, CD / analysis ; Antigens, Differentiation, B-Lymphocyte / analysis ; Antigens, Viral / analysis ; B-Lymphocytes / physiology ; Burkitt Lymphoma ; Epstein-Barr Virus Nuclear Antigens ; Humans ; Lymphocyte Activation ; Membrane Proteins / genetics ; Receptors, Fc / analysis ; Receptors, IgE ; Tumor Cells, Cultured ; Up-Regulation References: Mol Cell Biol. 1987 Jul;7(7):2299-308. (PMID: 3039344) ; Proc Natl Acad Sci U S A. 1987 Jul;84(13):4567-71. (PMID: 3037521) ; EMBO J. 1987 Sep;6(9):2743-51. (PMID: 2824192) ; J Virol. 1987 Dec;61(12):3870-8. (PMID: 2824821) ; Proc Natl Acad Sci U S A. 1987 Nov;84(22):8060-4. (PMID: 2825176) ; J Virol. 1988 Mar;62(3):894-901. (PMID: 2828684) ; J Virol. 1988 Jul;62(7):2337-46. (PMID: 2836616) ; Oncogene. 1988 May;2(5):461-7. (PMID: 2836780) ; Adv Cancer Res. 1988;50:95-158. (PMID: 2837072) ; Int J Cancer. 1988 Sep 15;42(3):329-38. (PMID: 2843473) ; J Virol. 1988 Oct;62(10):3747-55. (PMID: 2843672) ; J Virol. 1988 Nov;62(11):4173-84. (PMID: 2845129) ; J Exp Med. 1988 Dec 1;168(6):2059-75. (PMID: 2848918) ; J Virol. 1989 Feb;63(2):933-7. (PMID: 2536113) ; Proc Soc Exp Biol Med. 1967 Jan;124(1):107-11. (PMID: 4163469) ; Cancer Res. 1968 Jul;28(7):1300-10. (PMID: 4174339) ; J Exp Med. 1968 Nov 1;128(5):1011-20. (PMID: 4878906) ; Nature. 1970 Aug 15;227(5259):680-5. (PMID: 5432063) ; Int J Cancer. 1972 Jul 15;10(1):44-57. (PMID: 4122458) ; Int J Cancer. 1973 May;11(3):499-520. (PMID: 4133943) ; Hum Pathol. 1974 Sep;5(5):551-65. (PMID: 4368691) ; Virology. 1979 Apr 15;94(1):228-31. (PMID: 220786) ; J Immunol. 1983 Apr;130(4):1985-9. (PMID: 6300235) ; EMBO J. 1984 Apr;3(4):813-21. (PMID: 6327290) ; J Virol. 1984 Aug;51(2):411-9. (PMID: 6086953) ; Proc Natl Acad Sci U S A. 1984 Nov;81(22):7207-11. (PMID: 6095274) ; J Virol. 1985 Feb;53(2):528-35. (PMID: 2982035) ; J Virol. 1985 Sep;55(3):710-20. (PMID: 2991591) ; Cell. 1985 Dec;43(3 Pt 2):831-40. (PMID: 3000618) ; J Virol. 1986 Apr;58(1):233-7. (PMID: 3005654) ; J Virol. 1986 Jun;58(3):748-56. (PMID: 2422401) ; Immunology. 1986 Aug;58(4):591-5. (PMID: 2426189) ; J Virol. 1989 Apr;63(4):1531-9. (PMID: 2538644) ; Cell. 1989 Apr 7;57(1):5-7. (PMID: 2539260) ; J Virol. 1989 Jun;63(6):2768-72. (PMID: 2542588) ; J Virol. 1989 Jul;63(7):3135-41. (PMID: 2470924) ; J Gen Virol. 1989 Jul;70 ( Pt 7):1755-64. (PMID: 2544663) ; J Gen Virol. 1989 Nov;70 ( Pt 11):2989-3002. (PMID: 2479717) ; J Virol. 1990 Apr;64(4):1855-8. (PMID: 2157069) ; J Virol. 1990 May;64(5):2126-34. (PMID: 2157875) ; J Virol. 1990 May;64(5):2309-18. (PMID: 2157887) ; EMBO J. 1986 Oct;5(10):2599-607. (PMID: 3023050) ; J Virol. 1987 Apr;61(4):945-54. (PMID: 3029429) ; Proc Natl Acad Sci U S A. 1987 May;84(10):3452-6. (PMID: 3033649) ; J Gen Virol. 1987 Jun;68 ( Pt 6):1575-86. (PMID: 2438376) ; Eur J Immunol. 1987 Jun;17(6):815-20. (PMID: 3036539) ; Int J Cancer. 1987 Sep 15;40(3):358-64. (PMID: 3040601) Grant Information: 2R01 CA 30264 United States CA NCI NIH HHS Substance Nomenclature: 0 (Antigens, CD) ; 0 (Antigens, Differentiation, B-Lymphocyte) ; 0 (Antigens, Viral) ; 0 (Butyrates) ; 0 (EBV-associated membrane antigen, Epstein-Barr virus) ; 0 (Epstein-Barr Virus Nuclear Antigens) ; 0 (Membrane Proteins) ; 0 (Receptors, Fc) ; 0 (Receptors, IgE) ; 0 (Viral Matrix Proteins) Entry Date(s): Date Created: 19901101 Date Completed: 19901115 Latest Revision: 20200724 Update Code: 20240513 PubMed Central ID: PMC248595

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection.